Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials.

Jessica L Mega; Nathan O Stitziel; Gustav Smith; Daniel I Chasman; Mark J Caulfield; James J Devlin; Francesco Nordio; Craig L Hyde; Christopher P Cannon; Frank M Sacks; Neil R Poulter; Peter S Sever; Paul M Ridker; Eugene Braunwald; Olle Melander; Sekar Kathiresan; Marc S Sabatine

doi:10.1016/S0140-6736(14)61730-X

Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials.

Jessica L Mega, Nathan O Stitziel, Gustav Smith, Daniel I Chasman, Mark J Caulfield, James J Devlin, Francesco Nordio, Craig L Hyde, Christopher P Cannon, Frank M Sacks, Neil R Poulter, Peter S Sever, Paul M Ridker, Eugene Braunwald, Olle Melander, Sekar Kathiresan, Marc S Sabatine

Research output: Contribution to journal › Article › peer-review

Abstract

Genetic variants have been associated with the risk of coronary heart disease. In this study, we tested whether or not a composite of these variants could ascertain the risk of both incident and recurrent coronary heart disease events and identify those individuals who derive greater clinical benefit from statin therapy.

Original language	English
Pages (from-to)	2264-2271
Journal	The Lancet
Volume	385
Issue number	9984
DOIs	https://doi.org/10.1016/S0140-6736(14)61730-X
Publication status	Published - 2015

Subject classification (UKÄ)

Cardiac and Cardiovascular Systems

Access to Document

10.1016/S0140-6736(14)61730-X

http://www.ncbi.nlm.nih.gov/pubmed/25748612?dopt=Abstract

Cite this

Mega, J. L., Stitziel, N. O., Smith, G., Chasman, D. I., Caulfield, M. J., Devlin, J. J., Nordio, F., Hyde, C. L., Cannon, C. P., Sacks, F. M., Poulter, N. R., Sever, P. S., Ridker, P. M., Braunwald, E., Melander, O., Kathiresan, S., & Sabatine, M. S. (2015). Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. The Lancet, 385(9984), 2264-2271. https://doi.org/10.1016/S0140-6736(14)61730-X

@article{bd85bff600de42f49fcfa2c816cebc92,

title = "Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials.",

abstract = "Genetic variants have been associated with the risk of coronary heart disease. In this study, we tested whether or not a composite of these variants could ascertain the risk of both incident and recurrent coronary heart disease events and identify those individuals who derive greater clinical benefit from statin therapy.",

author = "Mega, {Jessica L} and Stitziel, {Nathan O} and Gustav Smith and Chasman, {Daniel I} and Caulfield, {Mark J} and Devlin, {James J} and Francesco Nordio and Hyde, {Craig L} and Cannon, {Christopher P} and Sacks, {Frank M} and Poulter, {Neil R} and Sever, {Peter S} and Ridker, {Paul M} and Eugene Braunwald and Olle Melander and Sekar Kathiresan and Sabatine, {Marc S}",

year = "2015",

doi = "10.1016/S0140-6736(14)61730-X",

language = "English",

volume = "385",

pages = "2264--2271",

journal = "The Lancet",

issn = "1474-547X",

publisher = "Elsevier",

number = "9984",

}

Mega, JL, Stitziel, NO, Smith, G, Chasman, DI, Caulfield, MJ, Devlin, JJ, Nordio, F, Hyde, CL, Cannon, CP, Sacks, FM, Poulter, NR, Sever, PS, Ridker, PM, Braunwald, E, Melander, O, Kathiresan, S & Sabatine, MS 2015, 'Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials.', The Lancet, vol. 385, no. 9984, pp. 2264-2271. https://doi.org/10.1016/S0140-6736(14)61730-X

TY - JOUR

T1 - Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials.

AU - Mega, Jessica L

AU - Stitziel, Nathan O

AU - Smith, Gustav

AU - Chasman, Daniel I

AU - Caulfield, Mark J

AU - Devlin, James J

AU - Nordio, Francesco

AU - Hyde, Craig L

AU - Cannon, Christopher P

AU - Sacks, Frank M

AU - Poulter, Neil R

AU - Sever, Peter S

AU - Ridker, Paul M

AU - Braunwald, Eugene

AU - Melander, Olle

AU - Kathiresan, Sekar

AU - Sabatine, Marc S

PY - 2015

Y1 - 2015

N2 - Genetic variants have been associated with the risk of coronary heart disease. In this study, we tested whether or not a composite of these variants could ascertain the risk of both incident and recurrent coronary heart disease events and identify those individuals who derive greater clinical benefit from statin therapy.

AB - Genetic variants have been associated with the risk of coronary heart disease. In this study, we tested whether or not a composite of these variants could ascertain the risk of both incident and recurrent coronary heart disease events and identify those individuals who derive greater clinical benefit from statin therapy.

U2 - 10.1016/S0140-6736(14)61730-X

DO - 10.1016/S0140-6736(14)61730-X

M3 - Article

SN - 1474-547X

VL - 385

SP - 2264

EP - 2271

JO - The Lancet

JF - The Lancet

IS - 9984

ER -

Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials.

Abstract

Subject classification (UKÄ)

Access to Document

Fingerprint

Cite this